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Abstract: This viewpoint is a global call to promote fundamental and applied research aiming 
toward designing smart nanocarriers of desired properties, novel noninvasive strategies to open 
the blood–brain barrier (BBB), delivery/release of single/multiple therapeutic agents across 
the BBB to eradicate neurohuman immunodeficiency virus (HIV), strategies for on-demand 
site-specific release of antiretroviral therapy, developing novel nanoformulations capable 
to recognize and eradicate latently infected HIV reservoirs, and developing novel smart 
analytical diagnostic tools to detect and monitor HIV infection. Thus, investigation of novel 
nanoformulations, methodologies for site-specific delivery/release, analytical methods, and 
diagnostic tools would be of high significance to eradicate and monitor neuroacquired immu-
nodeficiency syndrome. Overall, these developments will certainly help to develop personalized 
nanomedicines to cure HIV and to develop smart HIV-monitoring analytical systems for disease 
management.
Keywords: nanotherapeutics, personalized nanomedicine, smart monitoring analytical systems, 
HIV disease management
Discussion
Human immunodeficiency virus (HIV) is a deadly infectious disease and has 
been declared as a serious concern worldwide.1–3 The World Health Organization 
confirms .35 million HIV-infected people. Among them, 28 million people are eligible 
for antiretroviral therapy (ART). However, only 11.7 million could afford antiretroviral 
(ARV) drugs. In spite of significant advances in highly active ART, the elimination 
of HIV-1 reservoirs from the peripheral nervous system and central nervous system 
(CNS) remains an ultimate challenge.4 This is attributed to the integration of HIV-1 
genome with host genome, thereby causing viral latency in the periphery and in brain, 
as well. Furthermore, the inability of ART to penetrate the blood–brain barrier (BBB) 
after systemic administration makes brain as one of the most dominant HIV infection 
reservoirs.1 Developing the best suitable therapeutics for HIV demands multidisci-
plinary research and development approaches involving smart sensors, novel imaging 
agents, smart portable diagnostic tools, biomarkers, novel bioimaging, efficient affinity 
agents, smart assaying, real-time disease monitoring, and disease management systems 
to develop accessible cost-effective diagnosis and treatment for HIV patients.1
Advancements in analysis have proven a significant role in HIV diagnostics 
and monitoring of disease progression. The US Food and Drug Administration 
approved ~38 various anti-HIV drugs. The therapeutic effects of these drugs have been 
studied using advanced analytical tools and methods. In the present scenario, appreci-
ated efforts have been made to explore effective dual antiviral drugs and long-acting 
correspondence: Ajeet Kaushik
center for Personalized Nanomedicine, 
Institute of NeuroImmune Pharmacology, 
Department of Immunology, Herbert 
Wertheim college of Medicine, Florida 
International University, 11200 sW, 8th 
street, AHc-1, Lab 306, University Park, 
Miami, FL 33199, UsA
email ajeet.npl@gmail.com 
Journal name: International Journal of Nanomedicine
Article Designation: Perspectives
Year: 2016
Volume: 11
Running head verso: Kaushik et al
Running head recto: Nano-enabled therapeutics for neuroHIV
DOI: http://dx.doi.org/10.2147/IJN.S109943
Powered by TCPDF (www.tcpdf.org)
                               1 / 1
International Journal of Nanomedicine 2016:11submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
4318
Kaushik et al
(LA) drugs and vaccines to eradicate HIV infection without 
adverse effects. Recently, dual therapy, ie, an optimized 
cocktail of two ARV drugs, has been explored to manage HIV 
infection. A comprehensive review on the effects, advantages, 
and disadvantages of the dual therapy is described by Kelly 
et al.5 The authors claimed that the dual therapy containing 
tenofovir (Tef) exhibited more therapeutic advantages than 
triple therapy. However, the selection of appropriate drug 
according to the patient condition is very crucial because this 
therapy may reduce virologic efficacy in HIV-infected patient 
while lowering CD4 counts per high pre-ART HIV-1 RNA 
level. This report proposed that new nanoformulations (NFs) 
of LA cabotegravir (Ctg) and rilpivirine (Rpv) may have 
bright future prospects for HIV therapeutics. Such a viable 
dual therapy is useful to manage ART options and perfor-
mance, which lowers the costs and the globally unmet needs 
of pill-fatigued and adherence-challenged individuals.5
LA drugs, as HIV therapeutic agents, are in practice for 
HIV prevention due to their effective longer therapeutic 
effects at a very low dose in comparison to daily consump-
tion of ART. The strengths, weaknesses, opportunities, 
and challenges of LA-injectable therapies for HIV have 
been described excellently by Owen and Rannard.6 The 
pharmacology and formulation of LA Ctg were described 
in a comprehensive review presented by Trezza et al.7 The 
authors concluded that the pharmacologic profile of Ctg has 
great potential for the treatment and prevention of HIV-1 
infection. This drug exhibited half-life of 40 days and 
showed therapeutic action at a low dose. Thus, monthly and 
bimonthly oral administration in the form of tablet would 
be enough to control HIV infection.7 The multi-component 
pharmacokinetic evaluation of LA Rpv, 300 mg, 600 mg, or 
1,200 mg (for 84 days), in 66 HIV-negative volunteers for 
preexposure prophylaxis was performed by Jackson et al.8 
The authors assessed ex vivo antiviral activity of cervicova-
ginal lavage and claimed that each Rpv dose exhibited effec-
tive therapeutic effect, lasting till 84 days, upon exposure to 
plasma and genital tract. This study is useful to decide the 
appropriate dose for HIV therapeutics.8 In another study, 
the safety, tolerance, and pharmacokinetics of LA Rpv 
(TMC278, 300 mg/mL) formulation on administration, single 
and multiple intramuscular injection, in healthy volunteers 
were assessed by Verloes et al.9 The outcomes of this study 
suggested that a clinically relevant plasma concentration of 
Rpv could be optimized via tuning LA formulation.9 Very 
recently, Margolis et al10 presented a multicenter study based 
on long-acting ARV treatment enabling trial, for Phase IIb, 
using HIV-infected adults (.18 years old). The results 
suggested that Ctg plus dual nucleoside reverse transcriptase 
inhibitors (NRTIs) therapy exhibited antiviral activity and 
Ctg (30 mg, once a day) plus Rpv (25 mg, once a day) 
also exhibited 96 weeks longer antiviral activity similar to 
efavirenz plus NRTIs. The authors claimed that the inject-
able formulation of Rpv plus Ctg can be used as a two-drug 
regimen for HIV infection therapeutics.10
Besides significant advancements in ARV drug devel-
opment for HIV therapeutics, very few efforts were made 
to develop an effective anti-HIV vaccine. Gautam et al11 
demonstrated the long-term efficacy and protection evalu-
ation of passively transferred four anti-HIV-1-neutralizing 
monoclonal antibodies (VRC01, VRC01-LS, 3BNC117, 
and 10-1074), with a single high dose (20 mg/kg), in an 
HIV-infected monkey model. The authors claimed that a 
specific single neutralizing antibody demonstrated virus 
reduction up to 23 days. The results of this study suggested 
that all four antibodies showed plasma-neutralizing efficacy, 
which is dependent on antibody potency and half-life. Based 
on the outcomes, a specific anti-HIV antibody could be 
selected and injected to control high-risk transmission of HIV 
infection.11 To avoid the adverse effects of multitherapeutic 
agents, efforts are being made to design novel therapeutic 
agents that could work singly for activation and eradication 
of HIV infection. Guided genes, ie, CRISPR–Cas9/gRNA 
system, are recently being investigated to eradicate HIV in 
latently infected HIV reservoirs.3,12,13 Unfortunately, these 
studies were performed either in vitro or in periphery. HIV-
infected and latently infected HIV brain reservoirs could not 
be targeted due to negligible transmigration of therapeutics 
against HIV across the BBB.2 Therefore, efforts should be 
made to explore novel analytical science and nanotechnology 
for developing strategies to deliver therapeutics across the 
BBB to prevent neuroacquired immunodeficiency syndrome 
(neuroAIDS) in the brain.14
The major challenge to cure neuroHIV is the inability 
of effective anti-HIV therapeutic agents to cross the com-
plex integrity of the BBB. This makes HIV, ie, neuroHIV, 
incurable in the brain. Specific receptor binding,15,16 focused 
ultrasound,17 microbubble-assisted focused ultrasound,18 and 
magnetic field19-based approaches have been demonstrated 
to open the BBB for delivery of therapeutic agent. Receptor-
functionalized therapeutic cargos are bigger in size and thus 
affect efficacy, while an externally stimulated approach results 
in transient BBB opening, which may also allow the delivery of 
unwanted agents to the brain.20 Such agents, in the brain, may 
cause additional neuroinflammation and associated dementia. 
Recently, a noninvasive magnetically guided approach has 
been demonstrated by Kaushik et al.20 In this approach, the 
authors injected a biocompatible dose of magnetoelectric 
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nanoparticles (MENPs; 10 mg/kg), potential drug nanocarriers 
(NCs), into the mice brain via tail under a static magnetic field 
(0 T) for 3 hours to achieve CNS delivery. The transmission 
electron microscopy study conducted on the brain tissue 
of mice showed uniform distribution of MENPs in all cell 
types without agglomeration (Figure 1). Hematoxylin and 
eosin staining, blood toxicity assessment, and neurobehavior 
evaluation studies confirmed that the adopted methods using 
MENP are safe for living beings and also did not affect motor 
coordination function of mice.20
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Figure 1 Illustration of MENP delivery to the brain under the influence of static magnetic field (A). Ex-vivo TEM image of brain tissue of control (B) and MeNP-injected 
(C) mice.
Notes: MENPs are capable of navigating across the BBB (Ba vs Ca); direction of movement across tight junctions of layers of e is indicated by arrows. MeNPs are able to 
reach target sites, including N, A, and M, and are also observed in S, E, and blood cells (☼). Most MeNPs are uniformly distributed in the brain tissue/cells and are able to 
reach nucleus (dotted circles), but some agglomeration of MENPs in cell membranes and their entrapment in endosomes are also observed (solid arrow heads). *Represents 
synapses (Cc), J represents neuromuscular junction between S and the axon terminal (Ce). scale bars: 1 µm (Ba; Ca, b, and e) and 0.5 µm (Bb; Cc, d, and f). republished 
from Kaushik A, Jayant rD, Nikkhah-Moshaie r, et al. Magnetically guided central nervous system delivery and toxicity evaluation of magneto-electric nanocarriers. Sci Rep. 
2016;6:25309.20
Abbreviations: MeNP, magnetoelectric nanoparticle; teM, transmission electron microscopy; BBB, blood–brain barrier; e, endothelial cells; N, neurons; A, astrocytes; 
M, microglia; s, smooth muscle cells; sc, schwann cells; J, neuromuscular junction.
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The NCs of metal, metal oxides, gels, biopolymer, 
composites, and core-shell nanostructures are being designed 
and explored for binding of anti-HIV drugs and release of 
stimuli responses.2,20,21 The successful release of binded drugs 
is demonstrated in either a sustained or externally stimulated 
on-demand controlled manner. At present, developed NFs, ie, 
optimized combination of NCs and specific drug, were tested 
using an in vitro model that exhibited a high therapeutic effect 
and less adverse effect.1,21,22 Carson et al23 demonstrated a 
tunable sustained release of multiclass water-soluble (hydro-
philic) anti-HIV drugs, ie, Tef, using polyester-blended elec-
trospun fibers as a potential drug NC.23 The authors claimed 
that binding and release of anti-HIV drug was dependent 
on the affinity level between Tef and the functional groups 
available on the biocompatible fiber. This developed NF is 
able to carry high drug loading, ~40 wt%, and demonstrated 
sustained release from 24 hours to 30 days.23 However, this 
in vitro model needs to be confirmed using an in vivo model 
to evaluate the ability to cross the BBB. Destache et al24 
developed an NF containing Tef to prevent HIV-1 vaginal 
transmission in a humanized mouse model. The authors 
formulated Tef disoproxil fumarate at the nanoscale using a 
thermosensitive gel of poly(lactic-co-glycolic acid) prepared 
using oil-in-water emulsification. The efficacy of this formu-
lation was tested in humanized bone marrow–liver–thymus 
mice. The results of this study suggested that Tef disoproxil 
fumarate-NF acted as an LA drug via sustained release of 
Tef to show coitus-independent HIV-1 vaginal protection 
modality.24 Freeling et al25 developed an NF containing three 
LA anti-HIV drugs (lopinavir, ritonavir, and Tef) loaded in a 
lipid nanoparticle for longer exposure in primate plasma cells 
within lymph nodes (persistent HIV reservoirs) and blood to 
cure HIV infection. This developed NF showed 50-fold higher 
intracellular drug concentration in lymph in comparison 
to free drug administration. After single administration to 
plasma, the authors demonstrated that the intracellular drug 
level was enhanced until 7 days. Thus, the presented NF can 
be used as oral therapy for HIV at the periphery level.25
Roy et al26 developed an NF (140 nm) to eradicate HIV 
infection in the gut-associated lymphoid tissue (GALT), a reser-
voir of early HIV infection and host–pathogen interaction. The 
complex physiology of GALT resisted delivery of conventional 
anti-HIV drugs. Thus, developing NF specific to GALT is of 
high therapeutic importance. The authors explored paracellular 
transport property of M-cells for targeted delivery of pluronic 
NCs containing anti-HIV drug (efavirenz) functionalized with 
M-cell-specific antibody of the GALT. The sustained release of 
anti-HIV drug significantly reduced the HIV infection level in 
the GALT, compared to the free drug.26 Recently, nanomedicine 
technology has been explored to improve the efficacy of LA 
Rpv via developing an NF for pericoital and coitus-independent 
HIV infection therapeutics, demonstrated by Kovarova et al.27 
In this research, the authors binded Rpv with poly(lactic-co-
glycolic acid) nanoparticles and encapsulated them with a 
thermosensitive gel for delivery purpose. This NF, considered 
as solid nanosuspension of LA Rpv, was administrated intra-
muscularly in the bone marrow–liver–thymus mice. A single 
dose of this NF in mice, after a week, showed significant pro-
tection against high dose of vaginal challenge with HIV-1. The 
authors claimed that sometime in the presence of the antiviral 
drug, HIV infection may show systematic replication even on 
sustained release of ARV. Thus, implication of LA Rpv for 
HIV therapeutics is crucial and can be achieved by infecting 
such developed LA Rpv-based NF.27
To manage HIV-1 infection in the brain, significant efforts 
must be made to deliver this NF to the CNS. Numerous 
reports confirm that navigation across the BBB depends on 
the properties of NCs and NFs.1,2 Thus, exploring the prop-
erties of NCs and NFs independently is crucial to design an 
effective therapeutic cargo to cure HIV completely in the 
brain. However, the BBB always prevents the migration of 
NCs to the brain. Surface science has explored making the 
surface of NCs hydrophobic and generating functionality on 
NCs to bind with the BBB-related specific biomolecules, such 
as antibody, protein, and enzyme, to achieve CNS delivery. 
Externally controlled navigation strategy based on magnetic 
field and ultrasound strategy has recently been demonstrated 
for transmigration of NCs across the BBB.1,2
Recently, magnetic nanoparticles (MNPs) have been 
proposed as potential NCs to prepare effective NFs for the 
eradication of HIV in the brain and periphery.4,21 Jayant et al4 
developed layer-by-layer technology-based novel NFs con-
sisting of tef, vorinostat (a latency-breaking agent), and 
Fe
3
O
4
 (10±3 nm) as NCs for the treatment of neuroAIDS. 
The authors demonstrated magnetically guided delivery of 
this NF across the BBB and sustained release of both agents 
to activate and then eradicate HIV infection. The outcomes 
of this study suggested that loading and release of drug are 
dependent on layer-by-layer formulation later. This would 
help to monitor and control the pharmacokinetics. This NF 
showed sustained release of therapeutic agent over a period of 
5 days after HIV infection in primary human astrocytes, with 
good cell viability (90%).4 Raymond et al28 demonstrated the 
magnetically guided delivery of Nef peptides across the BBB 
using MNPs as NCs to induce microglial cytokine/chemokine 
secretion. The exNef is a novel mediator of HIV-induced 
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neuropathogenesis and could be modulated in the presence 
of Nef peptides. The successful delivery functionality of 
Nef peptides in the CNS may be useful to develop novel 
personalized nanomedicine for HIV therapeutics.28 Exter-
nally controlled on-demand controlled release of an NRTI, 
3′-azido-3′-deoxythymidine-5′-triphosphate (AZTTP), an 
anti-HIV drug, was demonstrated using MENPs as a potential 
nano drug carrier. An NF, consisting of MENPs and AZTTP, 
was formulated and magnetically delivered across the BBB.29 
An external alternating current (AC) magnetic field through an 
electromagnetic coil was applied to release AZTTP from NF. 
In this mechanism, MENPs showed polarization on AC 
magnetic field stimulation, which changed the electrostatic 
bond between MENPs and the bound drug. This phenom-
enon occurred rapidly and repeatedly, resulting in release 
of the drug from the surface of MENPs. MENP-based NFs 
were magnetically guided across the BBB, and 100% drug 
release was achieved via tuning the frequency and apply-
ing AC magnetic field. This NF significantly eradicated 
HIV-1 infection level across the BBB and has potential to 
be tested using animal models.21,29 It is well known that 
antiviral drug in CNS induces neuroinflammatory resulted 
in neurotoxicity. Recently, magnetically guided delivery 
of an anti-inflammatory agent, namely, tissue inhibitor of 
metalloproteinase-1 (TIMP1), across the BBB is demon-
strated to reduce HIV infection using MNPs as NCs and 
SK-N-MC neuroblastoma cells as in vitro model.30 This 
report claimed that TIMP1 reduced neuronal toxicity and 
significant recovery of spinal density and thus confirmed 
neuroprotective effects of TIMP1 in the CNS.30 The above 
discussed in vitro model showed impressive reduction in the 
HIV infection level across the BBB; therefore, efforts must 
be made to demonstrate these models in vivo to develop 
personalized nanomedicine to cure neuroHIV.
Besides successful in vitro demonstration, an NF, pre-
pared using biocompatible nanogels binded with NRTIs, was 
developed by Senanayake et al,31 and they claimed this NF 
as a novel antiviral agent of high efficacy to combat against 
HIV infection. This group developed a cationic nanogel, ie, 
cholesteryl-ε-polylysine, to encapsulate NRTI 5-succinate 
derivatives to evaluate anti-HIV activity using in vitro 
microphage model in the CNS as well. This NF demonstrated 
tenfold suppression in reverse transcriptase activity (EC90) 
in HIV-infected macrophage in comparison to single/double/
triple drug cocktails recommended for clinical trials.31 The 
sustained release of NRTIs for long time, enhanced efficacy, 
and biocompatible nature proposed this NF as a promising 
candidate to be tested in humanized mouse (hu-PBL) HIV 
model for the development of personalized nanomedicine. 
Recent success in the CNS delivery of ARV, ie, zidovudine 
(AZT), through the nasal route using chitosan microparticles 
(CP), prepared by spray drying techniques, as a carrier to cure 
brain HIV sanctuaries has been reported by Dalpiaz et al.32 The 
authors produced a prodrug via conjugating AZT with ursode-
oxycholic acid (UCDA–AZT) to overcome the issue of active 
efflux transporter systems. The UCDA–AZT (5 µM or 10 µM) 
system demonstrated 20 times higher efficacy than AZT to 
cure HIV in the CNS and in macrophages.32 To demonstrate 
delivery to rat brain, the authors administered this prodrug-
encapsulated CP through the nasal route, aiming to achieve 
high CNS uptake. The results suggested that utilization of CP 
increased the dissolution rate of UDCA–AZT and reduced 
water uptake, resulting in high levels in cerebrospinal fluid in 
rats, which is required for better efficacy in the CNS.32
Currently, scientists are exploring novel multi-functional 
NFs to block unwanted disorders in HIV-infected patients 
using substance of abuse.33 Sagar et al33 developed a highly 
selective magnetic NF for the delivery of a therapeutic 
agent to block the effects induced by morphine. A morphine 
antagonist, ie, d-Pen-Cys-Tyr-DTrp-Orn-Thr-Pen-Thr-NH2 
(CTOP), was bound with MNP and magnetically delivered 
across the BBB. Over time, release of CTOP showed signifi-
cant efficacy via protecting modulation of neuronal dendrite 
and spinal density. This NF was tested in HIV-infected 
cell lines, and outcomes were similar to those obtained in 
normal cell lines. In future, efforts must be made toward 
the encapsulation of NCs, anti-HIV drugs, and antagonists 
against substances of abuse to develop an effective NF. Such 
developed NFs would be capable of eradicating HIV infection 
and to block the effects induced by substances of abuse in 
HIV patients. The state-of-the-art and possible future strategy 
to eradicate and manage HIV is shown in Figure 2.
Nanoengineered NCs, highly sensitive technologies, and 
smart assays are being explored to develop an ideal nano-
medicine via improving properties of NCs, pharmacokinetics, 
and acceptable neurobehavioral alteration.34 During virus 
progression, the dysfunction of related biomarkers and genes 
has been quantified using sensitive analytical assays, namely, 
polymerase chain reaction, and enzyme-linked immunosor-
bent assay. Ultrasensitive histopathology, immunohistopa-
thology, and optical fluorescence imaging have been adopted 
recently to explore the biodistribution, pathogenesis, and 
toxicity of both NCs and NFs. Recently, transmission elec-
tron microscopy (Figure 1) with illuminating features was 
introduced to study the distribution of NCs in various organs 
to explain particle-to-particle interaction and elemental 
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composition of NCs over time after injection.20 Biodistribu-
tion and therapeutic effects of contrast agents containing NCs 
and NFs in the periphery and brain were studied using mag-
netic resonance imaging. The homeostatic effect of NCs in 
the living system was also studied using magnetic resonance 
imaging via real-time monitoring of contrast exposure.
It has been reported that HIV infection is serious, but it 
turns worst in combination with drugs of abuse. For example, 
HIV patients due to life style and ingestion of drug of abuse 
were found to be psychologically stressed which resulted 
in delayed response to therapeutics.35 Thus, stress monitor-
ing in HIV patients is crucial to decide therapeutics. Stress 
management of HIV patients has been declared necessary 
to obtain information for clinicians to avoid delay in thera-
peutics.35 The addition of such analytical devices is new to 
HIV therapy, but clinicians expect bright future prospects to 
assess social assessment impact of patients.36 The introduc-
tion of analytical sensing systems for HIV incidence will 
be of great significance.36,37 Enzyme-linked immunosorbent 
assay and real-time/quantitative polymerase chain reaction 
have demonstrated estimation of potential HIV biomarkers 
such as HIV-1 RNA viral load and CD4 cell counts. These 
methods have also quantified other HIV-infection-related 
biomarkers such as serum concentration of neopterin, beta-2 
microglobulin (IgA), interleukin-2 receptor, CD8 cell counts, 
anti-HIV antibodies, p24 antigen, hemoglobin level, platelet 
concentration, and erythrocyte sedimentation rate. Both 
these methods are very well established, but the need for 
high operation expertise and longer analysis time has raised 
the demand for rapid diagnostic tools to detect/monitor HIV 
infection in the physiological range. The available detection 
tools for detection of HIV biomarkers with performance 
parameters are summarized in Table 1.
Recently, electrochemical biosensing system has been 
developed to detect physiological stress markers in HIV 
patients. The electrochemical biosensors recently emerged as 
a potential analytical tool to detect target biomarkers at the 
picomolar level.38–41 Shafiee et al have described the available 
potential techniques to detect HIV biomarkers to estimate HIV 
infection level. This group also proposed that the develop-
ment of electrochemical system with features of affordability, 
sensitivity, specificity, user friendliness, rapidity, robustness, 
equipment-freeness, and desirability can be promoted at point-
of-care application to detect HIV infection for personalized 
health care.36 The performance of available detection tools to 
detect and monitor HIV infection is summarized in Table 2.
As per state of the art and according to ASSURED, 
a biosensor fabricated using a nanoplasmonic resonance 
detected ~100 copies/mL of HIV-1 subtype D using a 
very small volume (100 µL) of whole blood and plasma.42 
A label-free optical biosensor developed using a nanophotonic 
crystal was used to detect 104–106 copies/mL of HIV-1 in blood 
plasma.43 Such nanoenabled biosensors were operated simply 
with the salient feature of integration with nanosensing com-
ponents such as nanoelectronics, miniaturized transduction 
techniques, and microelectromechanical systems for detection 
of potential HIV-infection biomarkers (CD+ T lymphocytes 
and viral load) in the real sample, even at the point-of-care 
application.44–46 Using lab-on-chip-based approach, the 
capturing and quantification of CD+ lymphocytes has been 
demonstrated by Watkins et al.47 The authors reported that 
lab-on-chip functionalized by a specific antibody detected 
6XVWDLQHGUHOHDVHGPDQQHU%LRSRO\PHUEDVHGQDQRPHGLFLQH
([WHUQDOO\FRQWUROOHGRQGHPDQGGUXJUHOHDVH)RFXVHGXOWUDVRXQG(OHFWURPDJQHWLFILHOG
0DJQHWRHOHFWURDFWLYHQDQRPHGLFLQH
'ULYLQJIRUFHVQHHGHGWRQDYLJDWH1DQRPHGLFLQHDFURVV%%%YLD2QDSSO\LQJH[WHUQDOILHOG6XUIDFHSURSHUW\RIIRUPXODWLRQ
8OWUDVRXQGDFWLYHQDQRPHGLFLQH
/D\HUE\OD\HUDVVHPEOHGEDVHGQDQRPHGLFLQH
*HWWLQJLQWRWKHEUDLQWRFXUHQHXUR$,'6
%%%
1DQRPHGLFLQHVFURVV%%%RQWKHEDVHVRI)RUPXODWLRQZLWKLQQDQRVFDOHQP0DJQHWLFQDQRIRUPXODWLRQ(QJLQHHUHGVXUIDFHFKDUJH
2ULJLQDOZDYH
2EMHFW6HQGHUUHFHLYHU
5HIOHFWHGZDYH
'LVWDQFHU
Figure 2 state-of-the-art personalized nanomedicine to cure HIv and neuroAIDs.
Abbreviations: HIV, human immunodeficiency virus; neuroAIDS, neuroacquired immunodeficiency syndrome; BBB, blood–brain barrier.
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viral lysate ranging from 100 cells/mL to 700 cells/mL, 
with a detection limit of 9 cells/µL and a detection range 
from 100 cells/mL to 700 cells/µL.47 However, the detec-
tion of neuroHIV infection and also HIV incidences was not 
well explored by these sensing systems. Significant efforts 
should be made to investigate biomarkers for the detection of 
neuroHIV infection. The significance of neuroHIV monitoring 
and management using advanced nanoenabling sensing sys-
tems is described by Nair et al,1 as shown in Figure 3. Recently, 
electrochemical monitoring of HIV-infection in presence 
Table 1 Available analytical tools for detection of HIv infection
Techniques CD+ T lymphocytes 
counting
Viral load 
estimation
Remarks 
Flow cytometry conventionally well established  
for both
•	 Assay time: 8–40 minutes
•	 sample volume: 10 µL of blood
•	 Laboratory set-up
•	 Not suitable for POc
Image processing Bright field or fluorescent 
image of cD+ t lymphocytes
•	 Assay time: 20–30 minutes
•	 sample volume: 30 mL of whole blood
•	 Power: Ac battery
•	 Only qualitative
•	 Not suitable for POc
eLIsA centrifuge-based approach Nanoenabled eLIsA •	 Assay time: 40 minutes for cD+ and 48 hours for viral load
•	 sample volume: 30 µL of blood and 1 mL of plasma
•	 Power: Dc battery
rt-Pcr DNA based
virus capture based
•	 Assay time: 35–90 minutes
•	 sample volume: 150 µL of blood, 75 µL of fingerstick 
blood, and 1 mL of plasma
•	 Power: Ac/Dc battery
electrical sensing Best suitable for HIv detection  
and monitoring
•	 sensing time: 15–30 minutes
•	 sample volume: 10 µL
•	 Power: Ac battery/solar
•	 sensitive and selective
•	 suitable for detection and monitoring
•	 suitable for POc application
Abbreviations: HIV, human immunodeficiency virus; POC, point of care; AC, alternating current; ELISA, enzyme-linked immunosorbent assay; DC, direct current; 
rt-Pcr, reverse transcription polymerase chain reaction.
Table 2 A performance summary of available diagnostic tests/tools used to detect HIv infection
Diagnostic test/tool Detection technique and sensitivity/specificity
Low-cost, rapid HIv-monitoring tests:
•	 OraQuick rapid HIv-1/2 Antibody test
•	 Aware HIV-1/2 U (alternative to urine tests)
•	 Anti-HIV antibody and p24 antigen (for early infant diagnosis and for HIV-1 and 
HIv-2 subtype differentiation)
•	 HIV-1/2 Ag/Ab Combo (antigen and antibody)
•	 Oral fluids/blood sample (92.7%/100%)
•	 Blood/serum (88.7%/99.9%)
•	 ELISAs (12.5–200 pg/mL)
•	 Immunochromatographic (50%/86%)
HIv viral load monitoring:
•	 RT assay: (ExaVir Load)
•	 NAt: i) cOBAs Amplicor HIv-1 Monitor v1.5; ii) cOBAs AmpliPrep/cOBAs 
TaqMan v2.0; iii) Real-Time HIV-1; and iv) VERSANT HIV-1 RNA 1.0 Assay (kPCR)
•	 Non-NAT (HIV viral enzymes and proteins)
•	 p24 antigen technologies (NEN HIV-1 p24 ELISA)
•	 p24 antigen + anti-HIV, IgM, and IgG antibodies (HIV-1/2Ag/Ab Combo)
•	 rt activity in blood 200–600,000 copies/mL
•	 Detect and quantify viral RNA via RT-PCR
•	 50–750,000 copies/mL with 99.85% specificity
•	 N/A
•	 Detect and quantify HIV viral enzymes and proteins 
(10,000–30,000 RNA copies/mL)
•	 Detect blood p24 antigen (30,000–50,000 RNA copies/mL)
Microfluidics diagnostic:
•	 p24 test for eID
•	 cD4+ cells from whole blood (Daktari Diagnostics)
•	 Plasma (95%/99%)
•	 Whole blood (97%/86%)
POc:
•	 Ultrasensitive p24 Antigen Assay (NWGHF)
•	 PanNAt Diagnostic Platform
•	 Portable cD4+ T-cell count (PointCare NOW, CyFlow miniPOC)
•	 Heel-stick blood (95%/99%)
•	 Blood (95%/99%)
•	 Blood (90%/96%)
Abbreviations: HIV, human immunodeficiency virus; ELISA, enzyme-linked immunosorbent assay; RT, reverse transcription; NAT, nucleic acid-based tests; PCR, polymerase 
chain reaction; N/A, not applicable; eID, early infant diagnosis; POc, point of care.
Powered by TCPDF (www.tcpdf.org)
                               1 / 1
International Journal of Nanomedicine 2016:11submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
4324
Kaushik et al
1HXUR$,'6PRQLWRULQJDQGPDQDJHPHQW
,PDJHJXLGHGQHXUR$,'6IRUPRQLWRULQJ
94XDOLWDWLYHDQGVHPLTXDQWLWDWLYHDSSURDFK9'UXJGHOLYHU\DQGUHOHDVHPRQLWRULQJ9'LVHDVHSURJUHVVLRQ9'UXJHIILFDF\9%UDLQPDSSLQJ91HXURLPSDLUPHQWDVVHVVPHQW91HXUREHKDYLRUDODVVHVVPHQW
'UDZEDFNV
96RSKLVWLFDWHGHTXLSPHQW9([SHQVLYHDQGWLPHFRQVXPLQJ96RPHWLPHH[KLELWVFHOOGDPDJH91HHGWRGHYHORSQRYHOELRFRPSDWLEOHPXOWLIXQFWLRQDOLPDJLQJDJHQWV
1DQRHQDEOHGVPDUWDVVD\IRUQHXUR$,'6PDQDJHPHQW
96HOHFWLYHDQGVHQVLWLYHTXDQWLWDWLYHDSSURDFK93RUWDEOHDQGFDQEHXVHGDW32&9$59WKHUDS\99LUDOORDG&'FRXQWV9'UXJUHVLVWDQFH90RWKHUWRFKLOGWUDQVPLVVLRQ93URYLGHELRLQIRUPDWLFVIRUGLDJQRVWLFV
'UDZEDFNV
91HHGWRRSWLPL]HGHYLFHLQWHJUDWLRQZLWKUHGXFHGIRUPIDFWRUV
Figure 3 Performance comparison of analytical tools used to monitor and detect neuroHIv/AIDs.
Note: reprinted from Adv Drug Deliv rev, 103/1, Nair M, Jayant rD, Kaushik A, sagar v, Getting into the brain: potential of nanotechnology in the management of 
neuroAIDS, 202–217, Copyright (2016), with permission from Elsevier.1
Abbreviations: ARV, antiretroviral; neuroHIV, neurohuman immunodeficiency virus; AIDS, acquired immunodeficiency syndrome; BBB, blood–brain barrier; POC, point of care.
of cocaine and specific drugs related with HIV-infection 
and cocaine was demonstrated using an elctrochemical 
monitoring-on-chip (E-Moc) approach. Authors developed a 
cultureware chip and human astrocytes based in-vitro model 
for HIV-infection, Cocaine explore, treatment with Tef, along 
with rimcazole (RA, a cocaine antagonist). Electrochemical 
impedance spectroscopy was performed to evaluate electro-
physiology of cells during infection and therapeutic. Author 
claimed this methodology as an effective analytical tool for 
HIV-infection monitoring in various conditions.48
In summary, to cure HIV and neuroHIV/AIDS, we 
believe that significant research must be performed to design 
novel biocompatible NFs with salient features of target site 
delivery, novel easy mechanism to release ARV drugs, and 
effective CNS delivery to eradicate latent HIV infection. The 
investigation of novel diagnostic tools for detection of infec-
tion and its integration with NF-based HIV eradication will 
be useful to assess NF functionality with real-time monitoring 
of HIV infection. These significant advancements will help to 
decide HIV therapeutics and management. Therefore, we can 
say that involvement of new analytical diagnostic tools and 
nanoenabling formulations will simplify both HIV diagnosis 
and cure to manage personalized care.
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